PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 186 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2014. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $240,000 | +2.1% | 6,178 | +20.6% | 0.01% | 0.0% |
| Q3 2018 | $235,000 | -40.2% | 5,121 | +13.8% | 0.01% | -53.8% |
| Q2 2017 | $393,000 | +30.1% | 4,500 | 0.0% | 0.01% | 0.0% |
| Q3 2016 | $302,000 | -14.4% | 4,500 | 0.0% | 0.01% | -27.8% |
| Q4 2015 | $353,000 | +4.1% | 4,500 | 0.0% | 0.02% | 0.0% |
| Q3 2015 | $339,000 | -35.4% | 4,500 | 0.0% | 0.02% | -25.0% |
| Q2 2015 | $525,000 | -50.6% | 4,500 | 0.0% | 0.02% | -50.0% |
| Q1 2015 | $1,062,000 | +24.6% | 4,500 | 0.0% | 0.05% | +20.0% |
| Q4 2014 | $852,000 | -20.7% | 4,500 | 0.0% | 0.04% | -24.5% |
| Q3 2014 | $1,074,000 | +261.6% | 4,500 | 0.0% | 0.05% | +253.3% |
| Q2 2014 | $297,000 | -36.7% | 4,500 | 0.0% | 0.02% | -42.3% |
| Q1 2014 | $469,000 | +0.6% | 4,500 | 0.0% | 0.03% | +13.0% |
| Q4 2013 | $466,000 | +93.4% | 4,500 | 0.0% | 0.02% | +76.9% |
| Q3 2013 | $241,000 | – | 4,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 1,417,000 | $18,010,000 | 2.24% |
| Palo Alto Investors LP | 1,405,680 | $17,866,000 | 0.87% |
| PFM Health Sciences, LP | 2,838,376 | $36,076,000 | 0.68% |
| TANG CAPITAL MANAGEMENT LLC | 349,400 | $4,441,000 | 0.60% |
| Capital Impact Advisors, LLC | 127,029 | $1,615,000 | 0.59% |
| Leap Investments LP | 29,100 | $370,000 | 0.50% |
| Spark Investment Management LLC | 454,300 | $5,774,000 | 0.40% |
| Partner Investment Management, L.P. | 27,567 | $350,000 | 0.37% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 262,945 | $3,342,000 | 0.26% |
| Rock Springs Capital Management LP | 534,400 | $6,792,000 | 0.25% |